Novartis wins EU approval for Cosentyx in polymyalgia rheumatica
NVS•The European Commission approved Novartis’ Cosentyx for adults with polymyalgia rheumatica inadequately controlled by glucocorticoids or relapsing during tapering. In a Phase III trial, the drug doubled sustained remission rates versus placebo at Week 52.
1. EU approval
The European Commission cleared Cosentyx for adults with polymyalgia rheumatica inadequately controlled by glucocorticoids or relapsing during tapering. The Phase III REPLENISH trial showed the drug doubled sustained remission rates versus placebo at Week 52; reviews for the indication remain ongoing globally, including in the US and Japan.
